Clinical trials: Viral Load
Ebola Virus Disease
Efficacy of Favipiravir Against Ebola (JIKI)
There is no specific treatment for Ebola Virus Disease (EVD). Current EVD care are supportive, and includes intravenous or oral rehydration, nutrition, pain killers, treatment of coinfections with antibacterial and antimalarial…
- Trial name
- JIKI (NCT02329054)
- Testing
- Favipiravir
- Where
- 4 sites in Guinea
- Volunteers
- 126 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
HIV Infections
Optimised Electronic Patient Records to Improve Clinical Monitoring of HIV-positive Patients in Rural South Africa
In our formative research, analysis of antiretroviral treatment (ART) data manually entered in the Three Interlinked Electronic Registers (TIER.Net) showed poor viral load monitoring (VLM) and inadequate management of virological…
- Trial name
- MONART (NCT05071573)
- Testing
- Optimised electronic patient records
- Where
- South Africa
- Volunteers
- 1,500 people
- Sponsor
- University of Sussex
Hepatitis C
ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing
Hepatitis C virus (HCV) infection has become the leading fatal infectious disease in the United States. Approximately 75% of individuals who have been infected with HCV are chronically infected with the virus.
- Trial name
- NCT03767231
- Testing
- Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
HIV INFECTION
Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients
Phase II trial assessing the efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse…
- Trial name
- DARULIGHT (NCT02384967)
- Testing
- Darunavir
- Where
- France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections, Papillomavirus Infections
Viral Load Determination and Biomarkers of High Risk Human Papillomavirus (HPV) - Types in HIV-positive Men
Human papillomavirus (HPV)-infection belongs to the most common sexually transmitted diseases worldwide. HIV-infected men having sex with men (MSM) are strongly associated with a higher prevalence of genital HPV-infection, a…
- Conditions
- HIV Infections, Papillomavirus Infections, Anal Intraepithelial Neoplasia
- Trial name
- NCT00365729
- Testing
- Smear and biopsy testing for HPV-types and viral load
- Where
- 2 sites in Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Deutsche Luft und Raumfahrt
Cervical Intraepithelial Neoplasia
Evaluation of Initial High Risk Human Papillomavirus (HR-HPV) Viral Load as Predictive Marker for Cervical Intraepithelial Neoplasia Grade 1 (CIN1) Persistence
Relationship between HPV infection and cervical cancer is well established. Among the HPV types identified to date, 15 are classified as high risk HPV (HR-HPV).
- Trial name
- NCT00682552
- Testing
- A cervico-vaginal cervical smear
- Where
- France
- Volunteers
- 14 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
HIV Infection
Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals
The purpose of this study is to determine the safety, toxicity, dosing, and antiviral effects of epigallocatechin gallate (EGCG) in capsule form (Polyphenon® E), administered orally twice daily at three different doses in…
- Trial name
- NCT01433289
- Testing
- Polyphenon E
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Baylor College of Medicine
Risk Behavior, Medication Adherence
Secondary HIV Prevention and Adherence Among HIV-infected Drug Users
This study will test whether 3H+ (Holistic Health for HIV) is comparable to the original HHRP+ (Holistic Health Recovery Program) in reducing HIV risk behaviors and improving ART (Antiretroviral Therapy) adherence in a randomized…
- Conditions
- Risk Behavior, Medication Adherence, HIV
- Trial name
- NCT01741311
- Testing
- 3H+ (Holistic Health for HIV), HHRP+ (Holistic Health Recovery Program)
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- University of Connecticut
HIV-1 Infection
4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
Evaluate after 48 weeks, the capacity of a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment, in HIV-1 treated patients with undetectable viral load for at least 12 months and continuous…
- Trial name
- ANRS162-4D (NCT02157311)
- Testing
- Four consecutive days on treatment and 3 days off
- Where
- 17 sites in France
- Volunteers
- 100 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Liver Transplantation
Benefit of Immunoprophylaxis on Fibrosis to Reduce Viral Load After Liver Transplantation
An open-label randomized multicenter clinical study comparing three regimes of immunosuppression : (A) tacrolimus and steroids, (B) antithymocyte induction therapy and full dose of tacrolimus, (C) antithymocyte induction therapy…
- Trial name
- BEFIRTH (NCT00538265)
- Testing
- tacrolimus, tacrolimus, ATG, ATG+mycophénolate mofétil+tacrolimus
- Where
- 8 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Toulouse
HIV Infections, Pregnancy
Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy
The best anti-HIV treatment regimen for pregnant women is not known. Protease inhibitors (PIs) are often used, but they have side effects that may be harmful for pregnant women.
- Trial name
- NCT00017719
- Testing
- Lamivudine, Lamivudine/Zidovudine, Nelfinavir mesylate
- Where
- 49 sites in United States, Brazil and 2 more
- Volunteers
- 440 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Viremia, HIV -1 Infection
PERSON-CENTERED APPROACHES TO VIREMIA: CONNECTION, RAPPORT, AND ENGAGEMENT STUDY
The study aims to increase the reach of the person-centred interpersonal practices by developing and accessing a tailored, scalable, and sustainable approach that meets the distinctive needs of populations identified as most…
- Trial name
- P-CoRE (NCT07021092)
- Testing
- Interventions will be developed in aim 2 of the study.
- Where
- 2 sites in Zambia
- Volunteers
- 3,000 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
HIV Infections
HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)
This study will investigate low-level viral loads in HIV-infected patients taking highly active antiretroviral therapy (HAART). Although HAART reduces viral levels and restores immune function to some degree, it does not cure HIV…
- Trial name
- NCT00043641
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients
The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
- Trial name
- NCT00002195
- Testing
- Amprenavir, Lamivudine, Zidovudine
- Where
- 9 sites in United States
- Volunteers
- 290 people
- Sponsor
- Glaxo Wellcome
HIV Infections
A Randomized, Double-Blind Study of MKC-442 Combined With Viracept in Patients Who Are Epivir + Retrovir Experienced and Are Protease Inhibitor- and Non-Nucleoside Reverse Transcriptase Inhibitor-Naive
To compare the proportion of patients whose plasma HIV-1 RNA level falls and remains below the limit of quantification by the Roche Amplicor Monitor (400 copies/ml)[AS PER AMENDMENT 8/4/98: 50 copies/ml] between weeks 0 and 24.
- Trial name
- NCT00002215
- Testing
- Emivirine, Nelfinavir mesylate
- Where
- United States
- Sponsor
- Triangle Pharmaceuticals
Covid19
Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products
SARS COVID 2 has caused a pandemic of proportions unparalleled in the past 100 years. The virus has an uncanny ability for transmission and as such has been difficult to control.
- Trial name
- NCT04864925
- Testing
- Colgate Total Clean Mint, Tom's Botanically Bright Peppermint
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Colgate Palmolive
HIV Infections
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir
The purpose of this study is to see if 3 anti-HIV drug combinations are safe and effective in patients who have failed previous anti-HIV treatments using nelfinavir (NFV).
- Trial name
- NCT00006326
- Testing
- Indinavir sulfate, Ritonavir, Delavirdine mesylate
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Agouron Pharmaceuticals
Herpes Simplex, HIV Infections
The Effect of Acyclovir Treatment of the Herpes Simplex Virus (HSV) Infection on HIV Levels in the Blood
Part A: To evaluate the impact of HSV suppression with acyclovir ( ACV ) on HIV burden in patients with asymptomatic HSV infection and at high risk for HSV reactivation.
- Trial name
- NCT00001115
- Testing
- Acyclovir
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load
The purpose of this study is to determine if HIV-specific canarypox vaccine and/or interleukin-2 (IL-2) will control viral load (amount of HIV in the blood) after HIV treatment is withdrawn for a certain time period.
- Trial name
- NCT00013663
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection, HIV Infections
Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.
Darunavir boosted with ritonavir (darunavir/r) is a powerful protease inhibitor, able to reduce the viral load in patients infected with multi-resistant HIV strains; In vitro and in vivo studies have shown that the induction of…
- Trial name
- RADAR (NCT00849160)
- Testing
- darunavir
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida